Newsletter | December 1, 2025

12.01.25 -- Going Deep On Delivery With The Subcutaneous Consortium

SPONSOR

Eying The Drug Delivery Regulatory Landscape: The ‘Must See’ Watch List For 2026

Join Chief Editor Tom von Gunden as he engages drug delivery regulatory experts Rumi Young, John “Barr” Weiner, and Fran DeGrazio in a dynamic discussion of the current and near future regulatory landscape for drug and biologics delivery devices, systems, platforms, and combination products. Registration is free, sign up today!

FEATURED EDITORIAL

Going Deep On Delivery With The Subcutaneous Consortium

Officers from The Subcutaneous Drug Development and Delivery Consortium join for a videocast discussion of the association’s activities and outputs around bioavailability, immunogenicity, high dose formulations, sustainability, clinical development, regulatory strategy, and patient preference.

Growth And Advancements In Transdermal Drug Delivery

The transdermal drug delivery system industry is seeing significant growth. Let's look at new market research, including the advanced technologies being used and the therapeutic areas seeing the most impact.

INDUSTRY INSIGHTS

Microphysiological Systems: Closing The Gap Between Models And Medicine

Microphysiological systems (MPS) use human cells to model tissue function, offering faster, more predictive insights for drug discovery, safety testing, and personalized medicine.

Establishing And Safeguarding Shelf Life In Combination Products

Establishing combination product shelf life requires aligning stability. Holistic, data-driven stability studies ensure product function, safety, and label claims through the entire supply chain.

Meet Regulation Requirements With RTU Vials And Cartridges

Sterile manufacturing remains vital, with resilient supply chains preventing shortages. Industry and regulators prioritize integrity as demand surges, making it the fastest-growing pharmaceutical segment.

Sustainability Considerations For Drug Delivery Device End-To-End Solutions

Learn how to address the gradual unlinking of economic activity from the consumption of finite resources and the removal of waste to support and help prevent a global climate catastrophe.

Advancing Patient-Centric Drug Delivery For Neurodegenerative Disease

Pharmaceutical companies must prioritize patient-centric dosage forms to address challenges like dysphagia, enhance medication compliance, and improve therapeutic outcomes.

Leveraging Autoinjector Innovation To De-Risk Biosimilar Development

Discover how a biopharmaceutical company can de-risk the launch process by choosing a suitable autoinjector technology and partner.

De-Risking The Aseptic Drug-Filling Process And Optimizing Production

Aseptic drug-filling poses significant risks for manufacturers that can increase costs and timelines. Leveraging proven expertise and efficiency can ensure the production of safe, efficacious products.

SOLUTIONS

Our Small Molecule Development And Manufacturing Experience

Nasal Spray Development And Manufacturing Services

NanoImprove The Performance Of Your Biologic Formulation